You are here

aducanumab

Biogen Alzheimer's approval could open the door for other similar drugs

BioPharma Dive

Wed, 06/9/21 - 11:11 am

Alzheimer's disease

drug development

Biogen Sinks Despite Raft of Analyst Upgrades

Motley Fool

Tue, 06/8/21 - 09:43 pm

Alzheimer's disease

Ready, set, prescribe? Doctors detail why they'll deploy Biogen's new Alzheimer's drug—or not

Fierce Pharma

Tue, 06/8/21 - 12:31 pm

Alzheimer's disease

Aducanumab approval: ‘We anticipate demand will be high’, says Alzheimer’s Association

Biopharma Reporter

Tue, 06/8/21 - 12:30 pm

Alzheimer's disease

Biogen's 'shockingly broad' Aduhelm label—and $56K price—set up a $10B launch, analysts say

Fierce Pharma

Mon, 06/7/21 - 08:49 pm

Alzheimer's disease

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

Stat

Mon, 06/7/21 - 08:47 pm

Alzheimer's disease

U.S. FDA approves Biogen Alzheimer's drug

Reuters

Mon, 06/7/21 - 11:17 am

Alzheimer's disease

Biogen shares rise as FDA nears ruling on controversial Alzheimer's drug

Reuters

Mon, 06/7/21 - 11:05 am

Alzheimer's disease

With Action Date Imminent, Biogen's Aducanumab Invokes Hope and Skepticism

BioSpace

Thu, 06/3/21 - 10:59 pm

Alzheimer's disease

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

Stat

Mon, 05/31/21 - 06:56 pm

Alzheimer's disease

'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA

BioPharma Dive

Thu, 05/27/21 - 11:52 pm

Alzheimer's disease

Go or no go? Aducanumab’s day of reckoning

EP Vantage

Thu, 05/27/21 - 10:56 am

Ascendis Pharma

Alzheimer's patients face several hurdles if Biogen's Alzheimer's drug is OK'd

Beckers Hospital Review

Wed, 05/26/21 - 11:18 am

Alzheimer's disease

Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?

Endpoints

Thu, 05/6/21 - 10:57 am

Alzheimer's disease

Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market

Endpoints

Tue, 04/27/21 - 10:48 am

Michel Vounatsos

Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: analysts

Fierce Pharma

Wed, 04/21/21 - 11:29 pm

Alzheimer's disease

The next 2 months in biotech and pharma will be busy. Here's what to watch.

BioPharma Dive

Tue, 04/20/21 - 11:16 pm

Vertex Pharmaceuticals

Sarepta Therapeutics

FDA grew too close to Biogen during Alzheimer’s drug development, doctors say

Pharmaforum

Thu, 04/1/21 - 10:51 am

drug development

Alzheimer's disease

FDA advisers reassert case against approval of Biogen's Alzheimer's drug

BioPharma Dive

Wed, 03/31/21 - 10:55 pm

Alzheimer's disease

5 FDA approval decisions to watch in the second quarter

BioPharma Dive

Mon, 03/29/21 - 11:16 pm

Acadia Pharmaceuticals

Avalglucosidase alfa

pneumococcal disease

Pages